TransCode Therapeutics, Inc. publie des données précliniques soutenant le potentiel thérapeutique du TTX-MC138 dans le glioblastome

TransCode Therapeutics, Inc. a annoncé la publication de recherches précliniques soutenant l'application de son candidat ...

TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancer, today announced the ...
TipRanks on MSN

TransCode Therapeutics reports promising preclinical glioblastoma results

TransCode Therapeutics ( ($RNAZ) ) just unveiled an update. On January 6, 2026, TransCode Therapeutics announced the publication in the Journal of ...

Essai clinique de phase 2a de TTX-MC138 par Transcode Therapeutics attendu au premier semestre 2026

Transcode Therapeutics Inc : Transcode Therapeutics Inc : l'essai clinique de phase 2a de TTX-MC138 est attendu au premier ...
Investing.com France

L’action de TransCode Therapeutics s’envole après une étude prometteuse sur le glioblastome

Investing.com -- L’action de TransCode Therapeutics (NASDAQ:RNAZ) a bondi de 18% mardi après que la société a publié des données précliniques montrant que son candidat principal, TTX-MC138, a démontré ...
Investing.com France

La thérapie contre le glioblastome de TransCode montre des résultats prometteurs dans une étude préclinique

BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ) a annoncé aujourd’hui que son principal candidat thérapeutique, TTX-MC138, a démontré son efficacité dans des modèles précliniques de glioblastome m ...

TransCode Therapeutics stock soars after promising glioblastoma study

Investing.com -- TransCode Therapeutics (NASDAQ:RNAZ) stock surged 18% on Tuesday after the company published preclinical data showing its lead candidate TTX-MC138 demonstrated therapeutic potential ...

Biomednewsbreaks - Transcode Therapeutics, Inc. (NASDAQ: RNAZ) Publishes Preclinical Data Supporting TTX-MC138 For Glioblastoma

Publishes Preclinical Data Supporting TTX-MC138 For Glioblastoma. TransCode Therapeutics (NASDAQ: RNAZ) announced the publication of peer-reviewed preclinical research supporting the use of its lead ...
Hosted on MSN

TransCode announces collaboration for phase 2a trial

TransCode Therapeutics ( (RNAZ)) has shared an announcement. On December 11, 2025, TransCode Therapeutics announced a collaboration with Quantum Leap Healthcare Collaborative to evaluate their lead ...
Le Lézard

Marquis Who's Who Honors Jason A. Marks for Expertise in Health Care and Finance

UNIONDALE, NY / ACCESS Newswire / January 6, 2026 / Marquis Who's Who honors Jason A. Marks, MBA-HCM, for his expertise in ...
Yahoo Finance

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial

BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's ...
Le Lézard

Pathfinder Ventures Inc. Announces AGM Results and Stock Option Grants

VANCOUVER, BC / ACCESS Newswire / January 6, 2026 / Pathfinder Ventures Inc. (the "Company") announces the results of its Annual General and Special Meeting of shareholders (the "Meeting" ...